Metastatic castration-resistant prostate cancer: advances in treatment and symptom management
T Kulasegaran, N Oliveira - Current Treatment Options in Oncology, 2024 - Springer
Opinion statement The management of metastatic castrate-resistant prostate cancer
(mCRPC) has evolved in the past decade due to substantial advances in understanding the …
(mCRPC) has evolved in the past decade due to substantial advances in understanding the …
Intensification approaches and treatment sequencing in metastatic castration-resistant prostate cancer: a systematic review
Background and objective Recently, research on treatment intensification has gathered
momentum, and three novel therapy combinations were approved for metastatic castration …
momentum, and three novel therapy combinations were approved for metastatic castration …
Abiraterone, olaparib, or abiraterone+ olaparib in first-line metastatic castration-resistant prostate cancer with DNA repair defects (BRCAAway)
M Hussain, M Kocherginsky, N Agarwal… - Clinical Cancer …, 2024 - aacrjournals.org
Purpose: Deleterious germline/somatic homologous recombination repair mutations
(HRRm) are present in∼ 25% of patients with metastatic castration-resistant prostate cancer …
(HRRm) are present in∼ 25% of patients with metastatic castration-resistant prostate cancer …
Combination of PARP inhibitors and androgen receptor pathway inhibitors in metastatic castration-resistant prostate cancer
L Kostos, B Tran, AA Azad - Drugs, 2024 - Springer
Despite recent advances in the treatment of metastatic prostate cancer, progression to a
castration-resistant state remains inevitable for most and prognosis is limited. Genetic testing …
castration-resistant state remains inevitable for most and prognosis is limited. Genetic testing …
BRCA1, BRCA2, and Associated Cancer Risks and Management for Male Patients: A Review
Importance Half of all carriers of inherited cancer-predisposing variants
inBRCA1andBRCA2are male, but the implications for their health are underrecognized …
inBRCA1andBRCA2are male, but the implications for their health are underrecognized …
Navigating therapeutic sequencing in the metastatic castration-resistant prostate cancer patient journey
HD McManus, T Dorff, AK Morgans, O Sartor… - Prostate Cancer and …, 2024 - nature.com
Background Novel therapies for metastatic castration-resistant prostate cancer (mCRPC)
have improved patient outcomes. However, there is uncertainty on the optimal selection of …
have improved patient outcomes. However, there is uncertainty on the optimal selection of …
Genetics of prostate cancer: a review of latest evidence
R Hall, E Bancroft, N Pashayan, Z Kote-Jarai… - Journal of Medical …, 2024 - jmg.bmj.com
Prostate cancer (PrCa) is a largely heritable and polygenic disease. It is the most common
cancer in people with prostates (PwPs) in Europe and the USA, including in PwPs of African …
cancer in people with prostates (PwPs) in Europe and the USA, including in PwPs of African …
Intrapatient intermetastatic heterogeneity determined by triple-tracer PET imaging in mCRPC patients and correlation to survival: the 3TMPO cohort study
Intrapatient intermetastatic heterogeneity (IIH) has been demonstrated in metastatic
castration-resistant prostate cancer (mCRPC) patients and is of the utmost importance for …
castration-resistant prostate cancer (mCRPC) patients and is of the utmost importance for …
CRISPR/Cas9 screens identify LIG1 as a sensitizer of PARP inhibitors in castration-resistant prostate cancer
PARP inhibitors (PARPi) have received regulatory approval for the treatment of several
tumors, including prostate cancer (PCa), and demonstrate remarkable results in the …
tumors, including prostate cancer (PCa), and demonstrate remarkable results in the …
Prostate cancer therapy cardiotoxicity map (PROXMAP) for advanced disease states: a systematic review and network meta-analysis with Bayesian modeling of …
Background and objective Recommendations of first-line therapies for metastatic hormone-
sensitive (mHSPC), nonmetastatic castrate-resistant (M0CRPC), and metastatic castrate …
sensitive (mHSPC), nonmetastatic castrate-resistant (M0CRPC), and metastatic castrate …